Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Exelixis Inc 1851 Harbor Bay Parkway Alameda CA 94502 USA

www.exelixis.com P: 650-837-7000 F: 650-837-8300

Description:

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

Key Statistics

Overview:

Market Capitalization, $K 6,882,504
Enterprise Value, $K 6,619,514
Shares Outstanding, K 303,194
Annual Sales, $ 1,830 M
Annual Net Income, $ 207,770 K
Last Quarter Sales, $ 479,650 K
Last Quarter Net Income, $ 85,520 K
EBIT, $ 170,890 K
EBITDA, $ 196,610 K
60-Month Beta 0.54
% of Insider Shareholders 2.90%
% of Institutional Shareholders 85.27%
Float, K 294,401
% Float 97.10%
Short Volume Ratio 0.51

Growth:

1-Year Return 17.37%
3-Year Return -8.21%
5-Year Return 10.46%
5-Year Revenue Growth 114.35%
5-Year Earnings Growth -54.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.33 on 02/06/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm 0.64
EPS Growth vs. Prev Qtr 8,180.18%
EPS Growth vs. Prev Year 400.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

EXEL Ratios

Ratio
Price/Earnings ttm 35.64
Price/Earnings forward 18.78
Price/Earnings to Growth 0.60
Return-on-Equity % 8.57%
Return-on-Assets % 6.81%
Profit Margin % 11.35%
Debt/Equity 0.00
Price/Sales 3.78
Price/Cash Flow 29.62
Price/Book 3.05
Book Value/Share 7.47
Interest Coverage -1.47
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar